Navigation Links
Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
Date:2/24/2012

PITTSBURGH, Feb. 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Tony Mauro, president of Mylan North America and the company's Mylan Pharmaceuticals subsidiary, has been elected to serve as chairman of the Generic Pharmaceutical Association's (GPhA) board of directors. GPhA is an association that represents the world's leading generic drug manufacturers and suppliers. Mauro's election to this role further supports Mylan's mission to impact the future through passionate global leadership on the important issues and policies that shape the generic pharmaceuticals industry.

Mauro said: "I would like to thank the GPhA board of directors and membership for this opportunity, and also acknowledge Ralph Neas for his strong leadership of GPhA since joining the organization. I sincerely look forward to serving as chair and continuing to work closely with the board and Ralph during this truly monumental era in our industry. With growing populations, economic recessions and increasing health care costs, the need for widespread access to more affordable medicine has never been so great. The generic pharmaceutical industry, which accounts for 78% of all prescriptions dispensed in the U.S., has played an important role in saving the U.S. health care system and consumers an estimated $931 billion over the past decade."

"Generic drug makers also have stepped forward to assist the Food and Drug Administration (FDA) in addressing the industry-wide challenges, experienced by both brand and generics companies, caused by the globalization of the drug supply chain and the corresponding increase in the FDA's workload. This effort positions GPhA at the forefront of our industry's important issues, and advises policy makers that they should look to us as a key partner when tackling current and future challenges."

Mauro's term as chairman of GPhA will last for
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Mylan Secures an Additional $300 Million of Committed Financing
2. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
3. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
4. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
5. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
6. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
7. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
8. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
9. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
10. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
11. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com ... China Pharmaceutical Guidebook Series (4) 2013 Edition Material ... for Imported Drug Registration: A Guidebook of Registration ... Medicines " to its online database. ... Chinese medicines are always regarded by occidental as ...
(Date:5/22/2013)... and VANCOUVER, British Columbia , May 22, ... a leader in the development of novel therapeutics to target ... trials of its investigational compounds, custirsen and OGX-427, will be ... Annual Meeting of the American Society of Clinical Oncology ... 31 – June 4. Despite the availability ...
(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...
Breaking Medicine Technology:China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13
... of Inflammatory ... ... MOUNTAIN VIEW, Calif., May 13 ChemoCentryx, Inc., today,announced the initiation ... molecule compound designed to specifically,target the CCR1 chemokine receptor which is ...
... Business, DUBLIN, Ohio, May 12 Cardinal ... improve the safety and,productivity of health care, today ... privately held Enturia, Inc., the manufacturer of,infection prevention ... ChloraPrep(R) brand products are used widely in U.S. ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Cardinal Health Completes Enturia Acquisition 2
(Date:5/22/2013)... Boston, MA New research from Brigham and Women,s ... pulmonary fibrosis, an uncommon but deadly lung disease, may ... disease. These findings will be presented at the ... at the New England Journal of Medicine ... 4, 2013 print edition., "While this variant of the ...
(Date:5/22/2013)... Mathews from the University of Melbourne said this small ... undoubted benefits from CT scans in diagnosing and monitoring ... British Medical Journal today and involved researchers ... the International Agency for Research on Cancer in Lyon, ... very useful in providing detailed three dimensional pictures to ...
(Date:5/22/2013)... from a large observational study reported at ... superior to heparin in the absence of ... patients with non-ST segment elevation acute coronary ... European and US NSTE-ACS guidelines currently recommend ... heparin plus GP IIb/IIIa receptor inhibitors in ...
(Date:5/22/2013)... 2013, PHILADELPHIA ─More than 40 percent of patients ... clinic did not have the disease, researchers found ... "gold standard" for chronic obstructive pulmonary disease. , ... under-diagnosis of COPD, there has not been a ... over-diagnosis," said Christian Ghattas, MD., MSc, a ...
(Date:5/22/2013)... CO and Purchase, NY (PRWEB) May 22, 2013 ... has formed an exclusive partnership with Aurora ... an innovative marketing tool to companies that offer ... health card rewards members for completing 3 out ... The healthcare incentive product launched March 2013, and ...
Breaking Medicine News(10 mins):Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:Registry questions superiority of bivalirudin over heparin 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Integrated Printing Solutions and Aurora Financial Systems, Inc. Create Partnership for Healthcare Incentive Card 2
... U.S. organ transplant system often fails to detect or fix ... according to the Los Angeles Times on Sunday. ... are usually kept a secret leaving patients and their families ... ,This nonprofit agency has been given the contract ...
... at the Indian Institute of Technology (IIT), Chennai, have ... them into cells, a// major step towards drug efficacy. ... that comprises a core of one material and a ... of delivering therapeutic molecules into cells and monitoring it ...
... 80% accuracy in prediction of the most effective drug against ... test that examines the// genetic material of a patient’s tumour. ... North Carolina report that this genomic test is useful in ... a particular cancer but also a combination of drugs. ...
... chefs are two to four times bigger than the government's ... contributing to increasing weight of their diners, the chefs believe ... ,These were the findings that were revealed by a ... the Obesity Society. ,A meal at a restaurant ...
... and bad news for women faced with the decision about ... is that screening mammography does reduce breast cancer mortality. The ... less likely to die of breast cancer than women who ... that women in a screened population are 30 percent more ...
... provide a scientific basis for eventual treatment, neurology researchers ... of a protein that// helps keep brain activity in ... to be an underlying reason for seizures and memory ... brain injury (TBI). ,“A traumatic brain injury ...
Cached Medicine News:Health News:Flaws Reported in overview of US organ transplants 2Health News:Now, Silica Nanobubbles for Targeted Drug Delivery 2Health News:Genomic tests for better cancer treatment 2Health News:Portion Sizes in Restaurants Larger than Before 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 3Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 4Health News:How Brain Injury Leads to Seizures, Memory Problems 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: